Firms and Funds

Charlemagne raises €30m for its unique offering

Industri Kapital sold Danish electrical goods retailer - F Group

The Polish private equity firm sold its interest in loan broker Dom Finansowy

Ex-Biofocus CEO heads new company

Zero2IPO, a research firm that tracks the Chinese venture capital market, is working with Silicon Valley’s Startup Capital Ventures to raise a VC fund.Zero2IPO, which is based in Beijing, filed a document with the Securities and Exchange Commission declaring its intent to raise the fund, which is listed as Zero2IPO China Angel Fund I and […]

True Ventures, a venture firm based in San Francisco, has raised $77 million for its first fund, according to a regulatory filing. The firm expects to close on $100 million by the end of the year. The fund counts Paul Capital Partners, Sequoia Holdings and Park Street Capital among its 22 accredited investors. Founded by […]

Swiss alternative asset specialists Partners Group has raised €282m for its final close of Partners Group Global Mezzanine 2005, beating its €250m target. The fund will aim to invest 70% in mezzanine funds, with the remaining 30% focused on direct mezzanine tranches on private equity backed deals. Partners Group has already committed 55% of the […]

German mid-market buyout firm Deutsche Beteiligungs AG (DBAG) has made €98m following the IPO of portfolio company Bauer, a German building company, on the Frankfurt Stock Exchange. The initial share price for Bauer at IPO was €16.75 per share, towards the bottom of its €16.50 to €21.50 offer range, raising €135m and giving it a […]

ABN AMRO Capital is acquiring Amtico International, a manufacturer of high end flooring, from Electra Private Equity in a secondary buyout transaction. The sale of the £98.25m business is expected to complete in four weeks. As a result of the buyout, ABN AMRO Capital will acquire a 56% stake in Amtico. The company’s management team […]

Gilde Healthcare Partners, the Dutch venture firm, has held a first closing of Gilde Healthcare II (GHC II) on €85m, with a final closing on at least €125m anticipated later in the year. Banks invested 47% of the capital raised so far, with fund-of-funds investing 24%, pension funds 11%, 6% from biotech cross-over funds and […]